The medical laboratory is a supporting pillar of modern healthcare. Laboratory findings with analyses of blood, urine and other body fluids provide valuable insights from infection diagnostics and innovative screening procedures to therapy monitoring. Here you will find information on sample management, pre- and postanalytics, clinical chemistry, haematology and much more.
At the San Antonio Breast Cancer Symposium (SABCS), three experts presented new approaches and study results for the treatment of breast cancer in young women.
Using AI and extensive analyses of gene activity in tumours, researchers have found new, precise biomarkers to diagnose prostate cancer at an early stage through a simple urine sample.
Fighting pancreatic cancer can feel like a race against time. A new discovery could give clinicians a head start - by targeting precancerous lesions before they become much more aggressive.
In today’s fast-paced healthcare landscape, efficiency and accuracy are essential in overcoming workload challenges. Pathology laboratories are under pressure to keep up with growing demands, all while ensuring standardised, consistent and high-quality results.
A newly-developed robot can detect medication side-effects in patients after heart arrhythmia treatment faster than a human doctor, while reducing the number of follow-up tests.
MRC Holland recently announced that five SALSA MLPA assays for the detection of hereditary breast and ovarian cancer (HBOC) syndrome were recently CE-marked for in vitro diagnostic (IVD) use under the new In-Vitro Diagnostic Regulation EU 2017/746 (IVDR).
The discovery of a 'biomarker panel' could have a profound impact on the ability to identify patients at risk of developing pancreatic cancer at an earlier stage, researchers hope.
This March, the city of Poznań in Poland will host experts from the laboratory industry for the third edition of the Labs Expo Laboratory Equipment and Technology Fair.
A new study measured how well breast cancer patients’ tumour ‘explants’ respond to chemotherapy or HER2 antibody therapy in the laboratory. This could help improve clinical outcomes.
Sakura Finetek Europe and MEDIPATH, a group of independent French pathologists, announced their collaboration to enhance cancer diagnostics and thus contribute to improved patient therapeutic management. This decision is part of an ongoing commitment to improving the quality of care provided to patients and in response to the significant increase in cancer cases over the last years.
In the laboratory, researchers increased the bactericidal effect of antibiotics 64-fold with the use of a new hydrogel. The material made the antibiotics effective even against resistant bacteria.
New research highlights the potential of liquid biopsy in diagnosing pancreatic incidentaloma - lesions which can occasionally signal pancreatic cancer in its earliest stages.
Protection against blood clots: A new material, designed to mimic blood vessels, could allow for safer use of devices like catheters, stents, blood-oxygenation machines and dialysis machines.
Molecular pathology should become centralised in fewer labs to improve efficiencies and affordability, according to leading European experts.
Skills shortages and digitalization, trends in cardiology and oncology, future prospects in laboratory medicine, and healthy aging – these pressing topics are at the forefront of discussions at this year’s Medica Labmed Forum.
Researchers from China have developed ultrasensitive, nanoscale sensors that in small-scale tests distinguished a key change in the chemistry of the breath of people with lung cancer.
Increasing implementation of robotic automation and AI will speed up scientific progress in science laboratories, according to a new study. The experts outline this process across distinctive levels.
New insights into metastasis: Scientists created a 3D-printed model to mimic the specific conditions that spur the spread of cancer cells. This could help discover new screening and treatment options.
A newfound molecule, called ACBI3, could potentially lead to new therapies against hard-to-treat cancers, improving outcomes for all patients with cancers caused by KRAS mutations.
